Compare ProShares Ultra QQQ ETF (QLD) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Stryker Corporation — how do they compare? ProShares Ultra QQQ ETF trades at $90.12, while Stryker Corporation trades at $276.3 (market cap $106.03B). The key difference: Stryker Corporation pays a 1.27% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| QLD | SYK | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $100.53 | $388.79 |
52-Week Low | $57.16 | $275.39 |
Market Cap | — | $106.03B |
Enterprise Value | — | $117.50B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $90.53, down 0.17% with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, demonstrating powerful compounding. Recent institutional buying includes 180 Wealth Advisors increasing their position by 29.4% in Q2 2026. Technical indicators show strong moving average support but neutral oscillators, with key support at $88-90 and resistance at $91-93 levels.
As a daily leveraged ETF tracking the Nasdaq-100, QLD offers amplified exposure to large-cap tech but carries inherent volatility risks. The current neutral RSI and ADX suggest consolidation near support levels. Institutional accumulation and strong historical performance support long-term growth potential, though leveraged structure requires careful risk management during market turbulence.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
